Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06IIF
|
||||
| Former ID |
DNC009060
|
||||
| Drug Name |
1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexane
|
||||
| Synonyms |
1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
|
||||
| Indication | Discovery agent | Investigative | [529523] | ||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
|
||||
| InChI |
1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2
|
||||
| InChIKey |
BSMNRYCSBFHEMQ-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [531114] | |
| Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [529777] | ||
| Sodium-dependent dopamine transporter | Target Info | Inhibitor | [529523] | ||
| Sodium-dependent serotonin transporter | Target Info | Inhibitor | [529523] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesisP00001:Adrenaline and noradrenaline biosynthesis | ||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP706:SIDS Susceptibility Pathways | |||||
| Hematopoietic Stem Cell Differentiation | |||||
| Potassium ChannelsWP727:Monoamine Transport | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| Ref 529523 | Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. Epub 2008 May 23.Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. | ||||
| Ref 529777 | Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. Epub 2008 Oct 11.Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. | ||||
| Ref 531114 | Bioorg Med Chem Lett. 2010 Sep 15;20(18):5567-71. Epub 2010 Aug 17.Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.